Systems and methods of mitigating negative effects of therapies with transcutaneous vibration

1. A method to mitigate negative effects of a drug in a treatment of a mental health condition, the method comprising:

administering the drug to a subject in a controlled therapy session;

determining effects of the drug, the effects being counterproductive to the controlled therapy session; and

providing tactile stimulation to the subject with a stimulation device that generates transcutaneous vibratory output to be applied to a portion of a body of the subject during the controlled therapy session,

wherein the transcutaneous vibratory output is generated by a combination of oscillations, the combination of oscillations comprising a first oscillation at a first frequency and a second oscillation at a second frequency that together form an output with a first predetermined beat pattern,

wherein the first predetermined beat pattern is selected to reduce the counterproductive effects of the drug,

wherein the first predetermined beat pattern, in response to the effects being counterproductive, is adjusted from the first predetermined beat pattern to a second predetermined beat pattern over a time period in the controlled therapy session by adjusting at least one of the first frequency or the second frequency over the time period, and

wherein the second predetermined beat pattern is selected to reduce the counterproductive effects of the drug.

2. The method of claim 1 , wherein determining the effects of the drug further comprises utilizing sensors to generate biometric data of the subject.

3. The method of claim 2 , wherein the counterproductive effects of the drug comprise at least one of anxiety or restlessness.

4. The method of claim 1 , further comprising selecting the transcutaneous vibratory output based on the effects of the drug.

5. The method of claim 1 , further comprising applying a sensory stimulation to the subject.

6. The method of claim 5 , further comprising selecting the sensory stimulation based on the effects of the drug.

7. The method of claim 6 , wherein the sensory stimulation comprises visual stimulation.

8. The method of claim 6 , wherein the sensory stimulation comprises olfactory stimulation.

9. The method of claim 6 , wherein the sensory stimulation comprises taste stimulation.

10. The method of claim 1 , wherein the drug is selected from the group consisting of MDMA, psilocybin, cannabis, an anti-depressant, an anti-anxiety drug, an anti-psychotic, and a psychoactive drug.

11. The method of claim 1 , further comprising, multiplicatively combining a sine wave-shaped envelope generated using a perceived beat with a wave pattern generated using a perceived pitch to produce the transcutaneous vibratory output.

12. The method of claim 11 , wherein multiplicatively combining is in accordance with the relationship:

[sin(2.0*π*freq_perceived_pitch* t )]*[sin(π*freq_perceived_beat* t )].

13. The method of claim 1 , wherein the second frequency differs from the first frequency by less than 10 Hz.

14. The method of claim 1 , wherein an absolute value of a difference of the first frequency and the second frequency is less than 10 Hz.

15. The method of claim 1 , further comprising adjusting an intensity of the second pattern to maintain a same subjective intensity as the first pattern.

16. The method of claim 1 , further comprising adjusting an intensity of the second pattern as a function of the frequency of the second pattern.

17. A method to mitigate negative effects of a drug in a treatment of a mental health condition, the method comprising:

administering the drug to a subject in a controlled therapy session;

determining effects of the drug, the effects being counterproductive to the controlled therapy session;

providing tactile stimulation to the subject with a stimulation device that generates transcutaneous vibratory output having a selected envelope and a selected base tone to be applied to a portion of a body of the subject during the controlled therapy session; and

wherein the transcutaneous vibratory output is selected to reduce the counterproductive effects of the drug, and

wherein the transcutaneous vibratory output has a first predetermined beat pattern and the first predetermined beat pattern, in response to the effects being counterproductive, is adjusted to a second predetermined beat pattern over a time period in the controlled therapy session.

18. The method of claim 17 , further comprising selecting the selected envelope based on the effects of the drug.

19. The method of claim 17 , further comprising selecting the selected base tone based on the effects of the drug.

20. The method of claim 17 , wherein determining the effects of the drug further comprises utilizing sensors to generate biometric data of the subject.

21. The method of claim 17 , wherein the counterproductive effects of the drug comprise at least one of anxiety or restlessness.

22. The method of claim 17 , wherein the drug is selected from the group consisting of MDMA, psilocybin, cannabis, an anti-depressant, an anti-anxiety drug, an anti-psychotic, and a psychoactive drug.

23. The method of claim 17 , further comprising, multiplicatively combining the selected envelope generated using a perceived beat with the selected base tone generated using a perceived pitch to produce the transcutaneous vibratory output.

24. The method of claim 23 , wherein multiplicatively combining is in accordance with the relationship:

[sin(2.0*π*freq_perceived_pitch* t )]*[sin(π*freq_perceived_beat* t )].

25. The method of claim 17 , wherein the selected base tone is at a first frequency, and the selected envelope is at a second frequency that differs from the first frequency by less than 10 Hz.

26. A method of treating a subject comprising:

administering a drug during a controlled therapy session;

determining effects of the drug on the subject in the controlled therapy session, the effects being counterproductive to the controlled therapy session;

with a simulation device, applying to a portion of a body of the subject a transcutaneous vibratory output having a perceived pitch and a perceived beat; and

selectively altering the perceived pitch and the perceived beat to counteract counterproductive effects of the drug,

wherein at least one of the perceived pitch or the perceived beat are adjusted from a first frequency to a second frequency over a time period in the controlled therapy session.

27. The method of claim 26 , wherein determining the effects of the drug further comprises utilizing sensors to generate biometric data of the subject.

28. The method of claim 26 , wherein the drug is selected from the group consisting of MDMA, psilocybin, cannabis, an anti-depressant, an anti-anxiety drug, an anti-psychotic, and a psychoactive drug.

29. The method of claim 26 , wherein the counterproductive effects of the drug comprise at least one of anxiety or restlessness.

30. The method of claim 26 , further comprising, multiplicatively combining a sine wave-shaped envelope generated using the perceived beat with a wave pattern generated using the perceived pitch to produce the transcutaneous vibratory output.

31. The method of claim 30 , wherein multiplicatively combining is in accordance with the relationship:

[sin(2.0*π*freq_perceived_pitch* t )]*[sin(π*freq_perceived_beat* t )].

32. The method of claim 26 , wherein the transcutaneous vibratory output is generated in part by a first oscillation, and a second oscillation, wherein the difference between the frequencies of the first oscillation and the second oscillation is less than 10 Hz.